These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20353569)

  • 1. Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.
    Pepper DJ; Marais S; Wilkinson RJ; Bhaijee F; Maartens G; McIlleron H; De Azevedo V; Cox H; McDermid C; Sokhela S; Patel J; Meintjes G
    BMC Infect Dis; 2010 Mar; 10():83. PubMed ID: 20353569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial.
    Marcy O; Laureillard D; Madec Y; Chan S; Mayaud C; Borand L; Prak N; Kim C; Lak KK; Hak C; Dim B; Sok T; Delfraissy JF; Goldfeld AE; Blanc FX;
    Clin Infect Dis; 2014 Aug; 59(3):435-45. PubMed ID: 24759827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses.
    Pepper DJ; Rebe K; Morroni C; Wilkinson RJ; Meintjes G
    PLoS One; 2009; 4(2):e4520. PubMed ID: 19229341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of antiretroviral therapy in Cambodian hospital after diagnosis of tuberculosis: impact of revised WHO guidelines.
    Choun K; Pe R; Thai S; Lorent N; Lynen L; van Griensven J
    Bull World Health Organ; 2013 Mar; 91(3):195-206. PubMed ID: 23476092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.
    Fox MP; Sanne IM; Conradie F; Zeinecker J; Orrell C; Ive P; Rassool M; Dehlinger M; van der Horst C; McIntyre J; Wood R
    AIDS; 2010 Aug; 24(13):2041-50. PubMed ID: 20613459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa.
    Lawn SD; Myer L; Bekker LG; Wood R
    AIDS; 2007 Jan; 21(3):335-41. PubMed ID: 17255740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N; Uthman OA; Rutherford GW
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis.
    Ravimohan S; Tamuhla N; Steenhoff AP; Letlhogile R; Makutu DK; Nfanyana K; Rantleru T; Tierney A; Nkakana K; Schwartz AB; Gross R; Macgregor RR; Bellamy SL; Frank I; Weissman D; Bisson GP
    J Infect Dis; 2013 Dec; 208(11):1784-93. PubMed ID: 23908475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.
    Suthar AB; Lawn SD; del Amo J; Getahun H; Dye C; Sculier D; Sterling TR; Chaisson RE; Williams BG; Harries AD; Granich RM
    PLoS Med; 2012; 9(7):e1001270. PubMed ID: 22911011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.
    Blanc FX; Sok T; Laureillard D; Borand L; Rekacewicz C; Nerrienet E; Madec Y; Marcy O; Chan S; Prak N; Kim C; Lak KK; Hak C; Dim B; Sin CI; Sun S; Guillard B; Sar B; Vong S; Fernandez M; Fox L; Delfraissy JF; Goldfeld AE;
    N Engl J Med; 2011 Oct; 365(16):1471-81. PubMed ID: 22010913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demographic and clinical factors correlated with clinical outcomes among people with HIV treated by antiretroviral therapy: a retrospective cohort study.
    Li Y; Liu H; Zhang S; Zhang Y; Wang H; Zhang H; Li X
    BMC Infect Dis; 2024 May; 24(1):514. PubMed ID: 38778273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses.
    Takuva S; Westreich D; Menezes CN; McNamara L; Sanne I; Page-Shipp L; Maskew M
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1358-64. PubMed ID: 22863288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barriers to initiation of antiretrovirals during antituberculosis therapy in Africa.
    Pepper DJ; Marais S; Wilkinson RJ; Bhaijee F; De Azevedo V; Meintjes G
    PLoS One; 2011 May; 6(5):e19484. PubMed ID: 21589868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
    Havlir DV; Kendall MA; Ive P; Kumwenda J; Swindells S; Qasba SS; Luetkemeyer AF; Hogg E; Rooney JF; Wu X; Hosseinipour MC; Lalloo U; Veloso VG; Some FF; Kumarasamy N; Padayatchi N; Santos BR; Reid S; Hakim J; Mohapi L; Mugyenyi P; Sanchez J; Lama JR; Pape JW; Sanchez A; Asmelash A; Moko E; Sawe F; Andersen J; Sanne I;
    N Engl J Med; 2011 Oct; 365(16):1482-91. PubMed ID: 22010914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa.
    Komati S; Shaw PA; Stubbs N; Mathibedi MJ; Malan L; Sangweni P; Metcalf JA; Masur H; Hassim S
    AIDS; 2010 Jul; 24(12):1849-55. PubMed ID: 20622529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study.
    Marcy O; Tejiokem M; Msellati P; Truong Huu K; Do Chau V; Tran Ngoc D; Nacro B; Ateba-Ndongo F; Tetang-Ndiang S; Ung V; Dim B; Neou L; Berteloot L; Borand L; Delacourt C; Blanche S;
    Lancet HIV; 2018 Feb; 5(2):e87-e95. PubMed ID: 29174612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital.
    Mzileni MO; Longo-Mbenza B; Chephe TJ
    Pol Arch Med Wewn; 2008 Oct; 118(10):548-54. PubMed ID: 19112815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune reconstitution inflammatory syndrome presenting as chylothorax in a patient with HIV and Mycobacterium tuberculosis coinfection: a case report.
    Lin JN; Lai CH; Chen YH; Chang LL; Lee SS; Lin HH
    BMC Infect Dis; 2010 Nov; 10():321. PubMed ID: 21059235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.